Golidocitinib - Dizal Pharmaceutical
Alternative Names: AZD-4205; DZD-4205; JaupkoLatest Information Update: 02 May 2024
At a glance
- Originator AstraZeneca
- Developer Dizal Pharmaceutical
- Class Acetamides; Anti-inflammatories; Antineoplastics; Indoles; Piperazines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Peripheral T-cell lymphoma
- Phase II Non-small cell lung cancer
- Phase I Inflammatory bowel diseases
Most Recent Events
- 22 Feb 2024 Dizal Pharmaceuticals completes a phase I/II JACKPOT8 trial in Peripheral T-cell lymphoma (Second-line therapy or greater) in USA, Australia, South Korea, China (PO) (NCT04105010)
- 10 Jan 2024 Cancer Institute and Hospital, Chinese Academy of Medical Sciences in collaboration with Dizal Pharmaceuticals plans a phase II (JACKPOT33) trial in Non small cell lung cancer (Late-stage disease, Metastatic disease) in China (NCT06198907)
- 10 Dec 2023 Efficacy and safety data from a phase I/II JACKPOT8 trial in Peripheral T-cell lymphoma released by Dizal Pharmaceutical